eccogene glp 1 Announces First Patient Dosed in Phase 1b Trial of what companies make glp-1 drugs

Retatrutide is an investigational triple agonist that simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland

Graves' disease is often accompanied by an increase in heart rate, which may lead to further heart complications, including loss of the normal heart rhythm (atrial fibrillation), which may lead to stroke

Yadav, H., Lee, J.-H., Lloyd, J., Walter, P., & Rane, S

Tirzepatide's dual GLP-1 and GIP receptor activity produces slightly greater weight loss (up to 22% in SURMOUNT trials) and superior metabolic improvements in glucose control